UA66754C2 - Growth hormone secretion stimulators, intermediate compounds for the preparation thereof and pharmaceutical composition - Google Patents

Growth hormone secretion stimulators, intermediate compounds for the preparation thereof and pharmaceutical composition

Info

Publication number: UA66754C2
Authority: UA; Ukraine
Prior art keywords: growth hormone; compounds; useful; directed; accelerating
Prior art date: 1995-12-28

Application number

UA98063368A

Other languages

English (en)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-28

Filing date

1996-12-04

Publication date

2004-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21737850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA66754(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-12-04 Application filed by Pfizer filed Critical Pfizer

2004-06-15 Publication of UA66754C2 publication Critical patent/UA66754C2/xx

Links

150000001875 compounds Chemical class 0.000 title abstract 6
102000018997 Growth Hormone Human genes 0.000 title abstract 3
108010051696 Growth Hormone Proteins 0.000 title abstract 3
239000000122 growth hormone Substances 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
230000028327 secretion Effects 0.000 title 1
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
101710142969 Somatoliberin Proteins 0.000 abstract 2
229940011871 estrogen Drugs 0.000 abstract 2
239000000262 estrogen Substances 0.000 abstract 2
239000003324 growth hormone secretagogue Substances 0.000 abstract 2
230000013632 homeostatic process Effects 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 abstract 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract 1
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 abstract 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 abstract 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
229940122361 Bisphosphonate Drugs 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000017667 Chronic Disease Diseases 0.000 abstract 1
208000036119 Frailty Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
230000032683 aging Effects 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 abstract 1
229940062527 alendronate Drugs 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
206010003549 asthenia Diseases 0.000 abstract 1
-1 bisphosphonate compound Chemical class 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
230000001925 catabolic effect Effects 0.000 abstract 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract 1
108010070965 hexarelin Proteins 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
230000002503 metabolic effect Effects 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229940063238 premarin Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
238000011084 recovery Methods 0.000 abstract 1
230000004044 response Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Crystallography & Structural Chemistry (AREA)
Neurology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Cooling Or The Like Of Electrical Apparatus (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

UA98063368A 1995-12-28 1996-12-04 Growth hormone secretion stimulators, intermediate compounds for the preparation thereof and pharmaceutical composition UA66754C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US946995P	1995-12-28	1995-12-28
PCT/IB1996/001353 WO1997024369A1 (en)	1995-12-28	1996-12-04	Growth-hormone secretagogues

Publications (1)

Publication Number	Publication Date
UA66754C2 true UA66754C2 (en)	2004-06-15

Family

ID=21737850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA98063368A UA66754C2 (en)	1995-12-28	1996-12-04	Growth hormone secretion stimulators, intermediate compounds for the preparation thereof and pharmaceutical composition

Country Status (43)

Country	Link
US (7)	US6110932A (is)
EP (1)	EP0869968B1 (is)
JP (2)	JP3511382B2 (is)
KR (1)	KR100320167B1 (is)
CN (1)	CN1113895C (is)
AP (2)	AP756A (is)
AR (2)	AR004367A1 (is)
AT (1)	ATE361314T1 (is)
AU (1)	AU716934B2 (is)
BG (1)	BG64055B1 (is)
BR (1)	BR9612465B1 (is)
CA (1)	CA2241725C (is)
CO (1)	CO4480108A1 (is)
CZ (1)	CZ293423B6 (is)
DE (1)	DE69637063T2 (is)
DK (1)	DK0869968T3 (is)
EG (1)	EG24195A (is)
ES (1)	ES2285715T3 (is)
GT (1)	GT199600100A (is)
HN (1)	HN1996000085A (is)
HR (1)	HRP960618B1 (is)
HU (1)	HUP9901246A3 (is)
IL (4)	IL138911A (is)
IS (1)	IS4758A (is)
MA (1)	MA26415A1 (is)
MX (1)	MX9805157A (is)
MY (1)	MY135727A (is)
NO (1)	NO325135B1 (is)
NZ (1)	NZ322172A (is)
OA (1)	OA10702A (is)
PE (1)	PE30398A1 (is)
PL (1)	PL186916B1 (is)
PT (1)	PT869968E (is)
RS (1)	RS49926B (is)
SA (1)	SA97170581B1 (is)
SI (1)	SI0869968T1 (is)
SK (1)	SK285678B6 (is)
TN (1)	TNSN96172A1 (is)
TR (1)	TR199801233T2 (is)
TW (1)	TW432073B (is)
UA (1)	UA66754C2 (is)
WO (1)	WO1997024369A1 (is)
ZA (1)	ZA9610858B (is)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
GB2338235B (en)	1997-04-15	2001-11-14	Csir	Appetite suppressing plant extracts
GB2324726A (en) *	1997-05-01	1998-11-04	Merck & Co Inc	Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) *	1997-06-25	2003-02-17	Пфайзер Продактс Інк.	Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) *	1997-06-25	2004-03-15	Пфайзер Продактс Інк.	Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6251902B1 (en)	1997-06-25	2001-06-26	Pfizer Inc.	Dipeptide derivatives as growth hormone secretagogues
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
US6893877B2 (en) *	1998-01-12	2005-05-17	Massachusetts Institute Of Technology	Methods for screening substances in a microwell array
IL137007A0 (en)	1998-01-16	2001-06-14	Novo Nordisk As	Compounds with growth hormone releasing properties
US6657063B1 (en) *	1998-04-30	2003-12-02	Pfizer Inc.	Combinations of β3 agonists and growth hormone secretagogues
AU765851B2 (en) *	1998-06-03	2003-10-02	Pfizer Products Inc.	2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
JP2002518328A (ja) *	1998-06-16	2002-06-25	ファイザー・プロダクツ・インク	筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
PA8471201A1 (es) *	1998-06-16	2000-09-29	Pfizer Prod Inc	Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
HN1999000097A (es) *	1998-06-16	1999-11-03	Pfizer Prod Inc	Terapia de combinacion para la fragilidad muscoloesqueletica
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
US6358951B1 (en)	1998-08-21	2002-03-19	Pfizer Inc.	Growth hormone secretagogues
JP2002525274A (ja) *	1998-09-02	2002-08-13	メルクエンドカムパニーインコーポレーテッド	成長ホルモン分泌促進剤による独立生活状況への復帰促進
JP4854114B2 (ja)	1998-09-11	2012-01-18	シュミドマイヤー，ゲルハルド	生物学的に活性なインプラント
US6337332B1 (en)	1998-09-17	2002-01-08	Pfizer Inc.	Neuropeptide Y receptor antagonists
US6380184B1 (en)	1998-10-28	2002-04-30	Bristol-Myers Squibb Co.	Benzoazepines and analogs thereof useful as growth hormone secretagogues
US6194578B1 (en) *	1998-11-20	2001-02-27	Pfizer Inc.	Dipeptide derivatives
EP1486498A1 (en) *	1998-11-23	2004-12-15	Pfizer Products Inc.	Process and intermediates for growth hormone secretagogues
US6297380B1 (en)	1998-11-23	2001-10-02	Pfizer Inc.	Process and intermediates for growth hormone secretagogues
EP1158996A4 (en)	1999-02-18	2005-01-12	Kaken Pharma Co Ltd	NEW AMIDE SECRETAGOGUES OF GROWTH HORMONE DERIVATIVES
US6828331B1 (en)	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
US6541634B2 (en)	1999-02-26	2003-04-01	Pfizer Inc.	Process for preparing growth hormone secretagogues
US6518292B1 (en)	1999-03-12	2003-02-11	Bristol-Myers Squibb Co.	Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6525203B1 (en)	1999-03-12	2003-02-25	Bristol-Myers Squibb Company	Heterocyclic aromatic compounds useful as growth hormone secretagogues
CN1635898A (zh) *	1999-07-26	2005-07-06	贝勒医学院	超级活性的猪生长激素释放激素类似物
GB2396815B (en)	1999-10-27	2004-09-08	Phytopharm Plc	A composition comprising a pregnenone derivative and an NSAID
EP1113007A1 (en) *	1999-12-24	2001-07-04	Pfizer Inc.	Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
ATE304373T1 (de)	1999-12-28	2005-09-15	Kaken Pharma Co Ltd	Nervenschutzmittel
US20020151040A1 (en)	2000-02-18	2002-10-17	Matthew O' Keefe	Apparatus and methods for parallel processing of microvolume liquid reactions
US20010055765A1 (en) *	2000-02-18	2001-12-27	O'keefe Matthew	Apparatus and methods for parallel processing of micro-volume liquid reactions
EP1132388A3 (en)	2000-03-09	2004-03-03	Pfizer Products Inc.	Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1149583A3 (en) *	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DE60115227T2 (de)	2000-05-11	2006-08-24	Bristol-Myers Squibb Co.	Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
DOP2001000154A (es) *	2000-05-25	2002-05-15	Pfizer Prod Inc	Combinación de secretagogos de hormona del crecimiento y antidepresivos
EP1289526A4 (en)	2000-05-30	2005-03-16	Merck & Co Inc	MELANOCORTIN RECEPTOR AGONISTS
ATE446758T1 (de)	2000-05-31	2009-11-15	Pfizer Prod Inc	Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) *	2000-06-19	2002-04-21	Pfizer Prod Inc	The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) *	2000-06-29	2002-04-21	Pfizer Prod Inc	Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) *	2000-06-29	2002-04-10	Pfizer Products Inc.	Use of growth hormone secretagogues for stimulating or increasing appetite
GB2363985B (en)	2000-06-30	2004-09-29	Phytopharm Plc	Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144468A0 (en) *	2000-07-27	2002-05-23	Pfizer Prod Inc	Use of growth hormone secretagogues for improvement of functional health status
IL145106A0 (en) *	2000-08-30	2002-06-30	Pfizer Prod Inc	Intermittent administration of a geowth hormone secretagogue
AP2001002264A0 (en) *	2000-08-30	2001-09-30	Pfizer Prod Inc	Sustained release formulations for growth hormone secretagogues.
IL145540A0 (en) *	2000-09-28	2002-06-30	Pfizer Prod Inc	Use of growth hormone secretagogues in conjunction with physical exercise
US20100261159A1 (en)	2000-10-10	2010-10-14	Robert Hess	Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US6716629B2 (en) *	2000-10-10	2004-04-06	Biotrove, Inc.	Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
CA2372450A1 (en) *	2001-05-10	2001-09-19	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
US7125840B2 (en)	2001-10-09	2006-10-24	Eli Lilly And Company	Substituted dipeptides as growth hormone secretagogues
AU2002357692A1 (en)	2001-11-09	2003-05-26	Bristol-Myers Squibb Company	Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20030199514A1 (en) *	2002-03-27	2003-10-23	Fryburg David A.	Methods for improving efficacy of treatment with growth hormone secretagogues
US7396846B2 (en)	2002-04-09	2008-07-08	Eli Lilly And Company	Growth hormone secretagogues
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US8277753B2 (en) *	2002-08-23	2012-10-02	Life Technologies Corporation	Microfluidic transfer pin
WO2004027064A2 (en) *	2002-09-18	2004-04-01	Centre Hospitalier De L'universite De Montreal (Chum)	Ghrh analogues
US20060094108A1 (en) *	2002-12-20	2006-05-04	Karl Yoder	Thermal cycler for microfluidic array assays
EP1608952B1 (en)	2002-12-20	2016-08-10	Life Technologies Corporation	Assay apparatus and method using microfluidic arrays
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2004108120A1 (en) *	2003-06-11	2004-12-16	Pfizer Products Inc.	Use of growth hormone secretagogues for treatment of fibromyalgia
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
AU2004274309B2 (en)	2003-09-22	2010-04-08	Msd K.K.	Novel piperidine derivative
US7129561B2 (en) *	2003-11-19	2006-10-31	International Business Machines Corporation	Tri-metal and dual-metal stacked inductors
WO2005089945A1 (en)	2004-03-12	2005-09-29	Biotrove, Inc.	Nanoliter array loading
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
CA2561801A1 (en) *	2004-04-02	2005-10-20	Elixir Pharmaceuticals, Inc.	Sulfonamides and uses thereof
WO2005097174A2 (en) *	2004-04-07	2005-10-20	Gastrotech Pharma A/S	Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
US7381728B2 (en)	2004-07-28	2008-06-03	Glaxo Group Limited	Piperazine derivatives useful for the treatment of gastrointestinal disorders
US12070731B2 (en)	2004-08-04	2024-08-27	Life Technologies Corporation	Methods and systems for aligning dispensing arrays with microfluidic sample arrays
US20060105453A1 (en)	2004-09-09	2006-05-18	Brenan Colin J	Coating process for microfluidic sample arrays
KR101380200B1 (ko) *	2004-08-12	2014-04-01	헬신 세라퓨틱스 (유.에스.) 인크.	성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을촉진하는 방법
WO2006023608A2 (en)	2004-08-18	2006-03-02	Elixir Pharmaceuticals, Inc.	Growth-hormone secretagogues
CA2609388C (en)	2005-05-30	2013-08-06	Banyu Pharmaceutical Co., Ltd.	Novel piperidine derivative
JPWO2007018248A1 (ja)	2005-08-10	2009-02-19	萬有製薬株式会社	ピリドン化合物
EP1921065B1 (en)	2005-08-24	2010-10-20	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
WO2007029847A1 (ja)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	二環性芳香族置換ピリドン誘導体
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en)	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
US8158791B2 (en)	2005-11-10	2012-04-17	Msd K.K.	Aza-substituted spiro derivatives
WO2007058359A1 (ja) *	2005-11-21	2007-05-24	University Of Miyazaki	グレリン及びその誘導体又はＧＨＳ－Ｒ１ａに作用する物質を有効成分とする皮膚修復促進治療剤
US8273702B2 (en) *	2006-02-17	2012-09-25	Wake Forest University Health Sciences	Wound healing compositions containing keratin biomaterials
CU23592A1 (es) *	2006-02-28	2010-11-11	Ct Ingenieria Genetica Biotech	Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2012809B1 (en)	2006-03-10	2013-05-22	Ipsen Pharma	Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
JP5603074B2 (ja) *	2006-09-08	2014-10-08	ピラマルイメージングソシエテアノニム	１８ｆ標識物質のための化合物と方法
JP5489333B2 (ja)	2006-09-22	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	脂肪酸合成阻害剤を用いた治療の方法
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
US20090035215A1 (en) *	2006-10-02	2009-02-05	Ananth Srinivasan	Radiofluorination
US20080114055A1 (en) *	2006-11-10	2008-05-15	Zoltan Laboratories Llc	Thioxanthone Compounds to Reverse Weight Loss
KR20090107088A (ko)	2007-02-09	2009-10-12	트랜자임 파르마 인크	거대고리 그렐린 수용체 조절제 및 이의 사용 방법
MX2009009291A (es) *	2007-03-01	2009-12-14	Bayer Schering Pharma Ag	Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo.
US8877717B2 (en)	2007-03-12	2014-11-04	Zadec Aps	Anti-diabetic extract of rooibos
EP2002835A1 (en)	2007-06-04	2008-12-17	GenKyo Tex	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
CA2682727C (en)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Indoledione derivative
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2168602A4 (en) *	2007-06-12	2014-10-29	Inst Pharm & Toxicology Amms	LINEAR, PEGYLATED, SITE-SPECIFIC SALMON CALCITONIN DERIVATIVES
US20110015181A1 (en)	2008-03-06	2011-01-20	Makoto Ando	Alkylaminopyridine derivative
EP2272841A1 (en)	2008-03-28	2011-01-12	Banyu Pharmaceutical Co., Ltd.	Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
EP3241839B1 (en)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja)	2008-07-30	2010-02-04	萬有製薬株式会社	５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
EP2166009A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166010A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en)	2008-09-23	2010-03-24	Genkyo Tex Sa	Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010047982A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5635991B2 (ja)	2008-10-30	2014-12-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	イソニコチンアミドオレキシン受容体アンタゴニスト
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
EP2305679A1 (en)	2009-09-28	2011-04-06	GenKyoTex SA	Pyrazoline dione derivatives as nadph oxidase inhibitors
EP2361912A1 (en)	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) *	2010-02-18	2011-08-31	GenKyoTex SA	Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
JPWO2011105611A1 (ja) *	2010-02-26	2013-06-20	ラクオリア創薬株式会社	悪液質を治療するためのグレリン受容体作動物質
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
CN103547591A (zh) *	2011-04-21	2014-01-29	瑟瑞技术公司	生长激素释放因子(grf)类似物及其用途
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013175805A1 (en) *	2012-05-25	2013-11-28	Raqualia Pharma Inc.	Ghrelin receptor agonists for the treatment of achlorhydria
US9527875B2 (en)	2012-08-02	2016-12-27	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
TWI732158B (zh)	2012-09-27	2021-07-01	美商雅瑞塔那醫療公司	使用食慾喪失控制化合物之組合物及方法
WO2014065341A1 (ja)	2012-10-24	2014-05-01	第一三共株式会社	筋萎縮性側索硬化症治療剤
RU2015140066A (ru)	2013-02-22	2017-03-30	Мерк Шарп И Доум Корп.	Противодиабетические бициклические соединения
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
WO2014192294A1 (en) *	2013-05-28	2014-12-04	Raqualia Pharma Inc.	Polymorph forms
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
KR102051433B1 (ko) *	2013-08-27	2020-01-08	(주)네오팜	근육 분화 촉진 및 근육 강화용 조성물 및 외용제
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
RU2695649C2 (ru) *	2014-08-05	2019-07-25	Раквалиа Фарма Инк.	Производные серина в качестве агонистов грелиновых рецепторов
KR102431436B1 (ko)	2014-08-29	2022-08-10	테스 파마 에스.알.엘.	α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
EP3212648A1 (en) *	2014-10-31	2017-09-06	RaQualia Pharma Inc.	Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
AR109950A1 (es)	2016-10-14	2019-02-06	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3479843A1 (en)	2017-11-01	2019-05-08	GenKyoTex Suisse SA	Use of nox inhibitors for treatment of cancer
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN109320515A (zh) *	2018-11-22	2019-02-12	常州大学	一种Capromorelin手性中间体的不对称合成方法
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
CN120265641A (zh) *	2023-04-21	2025-07-04	长春金赛药业有限责任公司	GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) *	2024-10-09	2025-01-10	威海中腾医药科技有限公司	一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO136251C (no) *	1971-05-11	1977-08-10	Sandoz Ag	Analogifremgangsm}te for fremstilling av terapeutisk aktive pyridazin-derivater.
DE2221808C2 (de) *	1972-05-04	1985-06-20	Sandoz-Patent-GmbH, 7850 Lörrach	Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
IL107836A (en) *	1992-12-11	1998-01-04	Merck & Co Inc	Spiro piperidines and homologues, their preparation and pharmaceutical preparations containing them
JP3670690B2 (ja) *	1993-10-04	2005-07-13	トーアエイヨー株式会社	３−ピリダジノン誘導体、その製造法およびそれを含有する循環器官用剤
HUT75224A (en) *	1993-10-19	1997-04-28	Merck & Co Inc	Combination of bisphosphonates and growth hormone secretagogues
PL322706A1 (en) *	1993-11-09	1998-02-16	Merck & Co Inc	Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation
US5935924A (en) *	1994-04-15	1999-08-10	Genentech, Inc.	Treatment of congestive heart failure
US5610134A (en) *	1994-04-15	1997-03-11	Genentech, Inc.	Treatment of congestive heart failure
US5767118A (en) *	1994-10-26	1998-06-16	Merck & Co., Inc.	4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) *	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022997A1 (en) *	1995-01-27	1996-08-01	Novo Nordisk A/S	Compounds with growth hormone releasing properties
AU4534696A (en) *	1995-02-09	1996-08-27	Novo Nordisk A/S	Compounds with growth hormone releasing properties
WO1996024580A1 (en) *	1995-02-09	1996-08-15	Novo Nordisk A/S	Compounds with growth hormone releasing properties
WO1997007117A1 (en) *	1995-08-21	1997-02-27	Eli Lilly And Company	2-acylaminopropanamines as growth hormone secretagogues
CA2203428A1 (en) *	1995-08-21	1997-02-27	Philip Arthur Hipskind	2-acylaminopropanamides as growth hormone secretagogues
TW432073B (en) *	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

1996
- 1996-11-13 TW TW085113857A patent/TW432073B/zh not_active IP Right Cessation
- 1996-11-14 AP APAP/P/1996/000881A patent/AP756A/en active
- 1996-12-04 CZ CZ19981995A patent/CZ293423B6/cs not_active IP Right Cessation
- 1996-12-04 SK SK874-98A patent/SK285678B6/sk not_active IP Right Cessation
- 1996-12-04 DK DK96938434T patent/DK0869968T3/da active
- 1996-12-04 DE DE69637063T patent/DE69637063T2/de not_active Expired - Lifetime
- 1996-12-04 AU AU75850/96A patent/AU716934B2/en not_active Ceased
- 1996-12-04 CN CN96199388A patent/CN1113895C/zh not_active Expired - Lifetime
- 1996-12-04 ES ES96938434T patent/ES2285715T3/es not_active Expired - Lifetime
- 1996-12-04 TR TR1998/01233T patent/TR199801233T2/xx unknown
- 1996-12-04 AT AT96938434T patent/ATE361314T1/de not_active IP Right Cessation
- 1996-12-04 JP JP52412497A patent/JP3511382B2/ja not_active Expired - Lifetime
- 1996-12-04 KR KR10-1998-0704973A patent/KR100320167B1/ko not_active Expired - Lifetime
- 1996-12-04 PL PL96327634A patent/PL186916B1/pl not_active IP Right Cessation
- 1996-12-04 PT PT96938434T patent/PT869968E/pt unknown
- 1996-12-04 SI SI9630755T patent/SI0869968T1/sl unknown
- 1996-12-04 WO PCT/IB1996/001353 patent/WO1997024369A1/en not_active Ceased
- 1996-12-04 IL IL138911A patent/IL138911A/en not_active IP Right Cessation
- 1996-12-04 BR BRPI9612465-2A patent/BR9612465B1/pt not_active IP Right Cessation
- 1996-12-04 CA CA002241725A patent/CA2241725C/en not_active Expired - Lifetime
- 1996-12-04 HU HU9901246A patent/HUP9901246A3/hu unknown
- 1996-12-04 IL IL12444996A patent/IL124449A/en not_active IP Right Cessation
- 1996-12-04 IL IL13891096A patent/IL138910A0/xx unknown
- 1996-12-04 EP EP96938434A patent/EP0869968B1/en not_active Expired - Lifetime
- 1996-12-04 UA UA98063368A patent/UA66754C2/xx unknown
- 1996-12-04 NZ NZ322172A patent/NZ322172A/xx unknown
- 1996-12-04 IL IL13890996A patent/IL138909A0/xx unknown
- 1996-12-06 HN HN1996000085A patent/HN1996000085A/es unknown
- 1996-12-09 AR ARP960105571A patent/AR004367A1/es active IP Right Grant
- 1996-12-19 GT GT199600100A patent/GT199600100A/es unknown
- 1996-12-20 CO CO96066996A patent/CO4480108A1/es unknown
- 1996-12-23 ZA ZA9610858A patent/ZA9610858B/xx unknown
- 1996-12-24 MA MA24438A patent/MA26415A1/fr unknown
- 1996-12-24 TN TNTNSN96172A patent/TNSN96172A1/fr unknown
- 1996-12-24 EG EG117796A patent/EG24195A/xx active
- 1996-12-26 MY MYPI96005499A patent/MY135727A/en unknown
- 1996-12-26 RS YUP-702/96A patent/RS49926B/sr unknown
- 1996-12-27 PE PE1996000961A patent/PE30398A1/es not_active Application Discontinuation
- 1996-12-27 HR HR960618A patent/HRP960618B1/xx not_active IP Right Cessation
1997
- 1997-01-27 SA SA97170581A patent/SA97170581B1/ar unknown
1998
- 1998-05-26 IS IS4758A patent/IS4758A/is unknown
- 1998-06-11 BG BG102533A patent/BG64055B1/bg unknown
- 1998-06-19 OA OA9800090A patent/OA10702A/en unknown
- 1998-06-24 MX MX9805157A patent/MX9805157A/es active IP Right Grant
- 1998-06-26 NO NO19982991A patent/NO325135B1/no not_active IP Right Cessation
1999
- 1999-03-01 US US09/258,956 patent/US6110932A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,776 patent/US6124264A/en not_active Expired - Lifetime
- 1999-03-01 US US09/259,691 patent/US6107306A/en not_active Expired - Lifetime
- 1999-05-27 AP APAP/P/1999/001555A patent/AP860A/en active
- 1999-12-22 US US09/470,668 patent/US6278000B1/en not_active Expired - Lifetime
2000
- 2000-06-13 US US09/593,582 patent/US6306875B1/en not_active Expired - Lifetime
- 2000-06-13 US US09/593,581 patent/US6313140B1/en not_active Expired - Lifetime
- 2000-12-11 US US09/734,274 patent/US6482825B2/en not_active Expired - Lifetime
- 2000-12-20 JP JP2000386997A patent/JP2001213800A/ja active Pending
2006
- 2006-03-03 AR ARP060100824A patent/AR052506A2/es active IP Right Grant

Also Published As

Publication number	Publication date
US6107306A (en)	2000-08-22
EP0869968A1 (en)	1998-10-14
AP9600881A0 (en)	1997-01-31
HUP9901246A2 (hu)	1999-08-30
AP860A (en)	1999-08-06
US6110932A (en)	2000-08-29
AU7585096A (en)	1997-07-28
MA26415A1 (fr)	2004-12-20
ZA9610858B (en)	1998-06-23
RS49926B (sr)	2008-09-29
DE69637063T2 (de)	2008-02-07
NO325135B1 (no)	2008-02-04
MY135727A (en)	2008-06-30
PL327634A1 (en)	1998-12-21
US6124264A (en)	2000-09-26
US6313140B1 (en)	2001-11-06
US20020049196A1 (en)	2002-04-25
AR004367A1 (es)	1998-11-04
IL138909A0 (en)	2001-11-25
NZ322172A (en)	2000-08-25
IS4758A (is)	1998-05-26
AR052506A2 (es)	2007-03-21
TR199801233T2 (xx)	1998-10-21
AP756A (en)	1999-08-06
CN1113895C (zh)	2003-07-09
AU716934B2 (en)	2000-03-09
DK0869968T3 (da)	2007-09-10
US6306875B1 (en)	2001-10-23
ATE361314T1 (de)	2007-05-15
KR100320167B1 (ko)	2003-11-14
CN1206422A (zh)	1999-01-27
HN1996000085A (es)	1997-06-18
ES2285715T3 (es)	2007-11-16
AP9901555A0 (en)	1999-06-30
NO982991D0 (no)	1998-06-26
US6278000B1 (en)	2001-08-21
MX9805157A (es)	1998-10-31
IL138910A0 (en)	2001-11-25
IL124449A (en)	2004-06-01
CZ199598A3 (cs)	1999-05-12
CA2241725C (en)	2002-06-18
BR9612465A (pt)	1999-07-13
US6482825B2 (en)	2002-11-19
PL186916B1 (pl)	2004-03-31
TNSN96172A1 (fr)	2005-03-15
CZ293423B6 (cs)	2004-04-14
IL138911A (en)	2007-07-24
JP3511382B2 (ja)	2004-03-29
IL138911A0 (en)	2001-11-25
WO1997024369A1 (en)	1997-07-10
EP0869968B1 (en)	2007-05-02
SI0869968T1 (sl)	2007-08-31
BG64055B1 (bg)	2003-11-28
BG102533A (en)	1999-09-30
SK87498A3 (en)	1999-08-06
CA2241725A1 (en)	1997-07-10
IL124449A0 (en)	1998-12-06
SK285678B6 (sk)	2007-06-07
EG24195A (en)	2008-10-14
HRP960618B1 (en)	2007-12-31
OA10702A (en)	2001-05-07
JPH11501945A (ja)	1999-02-16
SA97170581B1 (ar)	2006-03-15
TW432073B (en)	2001-05-01
JP2001213800A (ja)	2001-08-07
CO4480108A1 (es)	1997-07-09
YU70296A (en)	1999-11-22
HRP960618A2 (en)	1998-04-30
HUP9901246A3 (en)	1999-11-29
BR9612465B1 (pt)	2010-08-10
GT199600100A (es)	1998-06-12
PE30398A1 (es)	1998-07-21
KR19990076846A (ko)	1999-10-25
DE69637063D1 (de)	2007-06-14
NO982991L (no)	1998-08-26
PT869968E (pt)	2007-07-11

Publication	Publication Date	Title
UA66754C2 (en)	2004-06-15	Growth hormone secretion stimulators, intermediate compounds for the preparation thereof and pharmaceutical composition
AP9801270A0 (en)	1999-12-18	Dipeptide derivatives.
MXPA03006951A (es)	2003-12-08	Secretagogos de hormona del crecimiento.
DK1002802T3 (da)	2005-03-14	Dipeptidderivater som væksthormonsecerneringsfremkaldende stoffer
AP1043A (en)	2002-02-04	Tartrate salt of a substituted dipeptide.
EP0635270A1 (en)	1995-01-25	Parathyroid hormone and raloxifene for increasing bone mass
JPH06511233A (ja)	1994-12-15	骨の形成を促進するための骨成長因子および骨吸収阻害剤
JP2011148814A (ja)	2011-08-04	軟骨および／または骨の症状の予防および／または治療のためのストロンチウムを用いる併用治療
WO1995003289A1 (en)	1995-02-02	Benzo-fused lactams promote release of growth hormone
WO1996002530A1 (en)	1996-02-01	Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US7038010B2 (en)	2006-05-02	Agents and methods for promoting bone growth
US7034050B2 (en)	2006-04-25	Pseudopeptides growth hormone secretagogues
Rosen	1995	Primary biliary cirrhosis and bone disease
US6923968B2 (en)	2005-08-02	Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
HUP0202167A2 (en)	2002-10-28	Calcilytic compounds
US6573291B2 (en)	2003-06-03	Method and use
WO2002057241A1 (en)	2002-07-25	8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO1998053827A1 (en)	1998-12-03	Treatment of osteoporosis
EP1756142B1 (en)	2008-07-02	Pseudopeptides growth hormone secretagogues
WO2002056873A2 (en)	2002-07-25	2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
JP2007502841A (ja)	2007-02-15	成長ホルモンの２０ｋＤａ胎盤性変種を用いる体形成療法
HK1102373B (en)	2008-09-12	Pseudopeptides growth hormone secretagogues